The NCBiotech Bio Defense program expands the life science base of North Carolina’s $38 billion defense economy.
Our Bio Defense outreach goes far beyond concerns over bioterrorism. NCBiotech and partners -- North Carolina’s small companies, researchers and military representatives -- are thinking more broadly. We work to provide vaccines for soldiers, to protect the food supply, and to find how best to deploy novel technologies that will protect our soldiers and heal those who sustain wounds in battle.
Information on North Carolina's Bio Defense companies in North Carolina can be found in the NCBiotech Company Directory.
For a complete list of all current COVID-19 company and research funding opportunities, please view our COVID-19 Resource webpage.
Given the size and significance of the federal investments in NC, NCBiotech and partners are working to bring the state’s innovative, life science technological expertise to bear to address critical challenges faced by the military and national security agencies. Developing strategies to better align the state’s well-recognized life science strengths with the Department of Defense (DoD) and national security strategic priorities will enable our state to be a critical solution provider on challenging problems while also increasing defense funding to support North Carolina researchers and companies.
Some of these NCBiotech-led activities include:
Providing support for university-based researchers and small businesses that have a technology that addresses a need in the Bio Defense arena and educate and support their efforts in seeking DoD or homeland security relationships and funding
Promoting and representing North Carolina at targeted military and federal Bio Defense conferences throughout the United States and promote our state's life science capabilities
Hosting or sponsoring conferences where military, government, academic and industry experts can network and collaborate
Connecting military, industry and academia partners to promote North Carolina’s Bio Defense capabilities at the state and federal level
For additional information, please see our Bio Defense Initiative one-pager.
Biomedical Advanced Research & Development Authority (BARDA)
BARDA is providing a portal for the U.S. government 2019 novel coronavirus (2019-nCoV) medical countermeasures task force to provide a single point of entry for the submission of market research packages from interested stakeholders.
Click here to view the portal website is:
At this time, BARDA is asking for a very brief (500-word) description of your product or technology, accompanied by a brief white paper, slide deck, manuscript, or other non-confidential information of your choosing. Please note that while BARDA will use any information you present as market research, submission is no guarantee of funding and your submission will be shared across U.S. Government agencies involved in nCoV medical countermeasure research and development.
BARDA Industry Day 2019 featured two days of exciting speakers, breakout sessions, and valuable networking opportunities.
The theme of BARDA Industry Day 2019 held October 15-16, 2019 in Washington, DC was "Catalyzing Health Security."
Copies of the presentations are now available online for review.
BARDA DRIVe Industry Day 2018 Presentations
BARDA remains committed to engaging industry and government partners to fulfill their mission, saving lives and protecting Americans through the research and development of medical countermeasures against serious health security threats.
The theme of BARDA Industry Day 2018 held October 29-30, 2018 in Washington, DC was "Driving Innovation." Copies of the presentations are now available online for review.
Presentations from the DRIVe Session on October 30 at 1:00 p.m. are also available below.
For future BARDA DRIVe opportunities, sign up for the listserv.
If you or your company are developing a medical countermeasure or platform technology to combat chemical, biological, radiological, or nuclear threats, pandemic influenza or other emerging infectious diseases, you can get insights and strategic advice from HHS/ASPR Biomedical Advanced Research and Development Authority (BARDA) at a TechWatch meeting.
BARDA TechWatch meetings are your chance to introduce your proposed solution that may meet one or more of BARDA’s current priorities, and are the beginning of an important dialogue.
TechWatch meetings can be a good way in which to also get insights from other professionals from other governmental agencies with related portfolios. They can take several weeks to a couple of months to schedule so take that into consideration in your planning.
View the Latest Updates From BARDA
BARDA Division of Research, Innovation and Ventures (DRIVe)
As part of the U.S. government's ongoing public health response to the 2019 novel coronavirus (2019-nCoV), the U.S. Department of Health and Human Services (HHS) today announced the opening of an Easy Broad Agency Announcement (EZ-BAA) for development of 2019-nCoV diagnostics and is now accepting abstract submissions for potential funding. Under this EZ BAA, the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), will review concise abstract submissions for development funding of 2019-nCoV molecular diagnostics. The diagnostics must utilize platforms already cleared by the U.S. Food and Drug Administration, with a viable plan to meet requirements for the FDA to consider Emergency Use Authorization (EUA) within 12 weeks of an award.
"Diagnostics in close proximity to the patient are essential to ensure appropriate, prompt care and to help curb the spread of infectious diseases such as 2019-nCoV," said BARDA Director Rick Bright, PhD. "The 2019-nCoV poses a serious global health challenge, and at BARDA we are working rapidly with our government and industry partners to accelerate development of medical products needed to help protect the health of the American people."
To read the full press release, please follow this link: https://www.hhs.gov/about/news/2020/02/05/hhs-seeks-abstract-submissions-for-2019-ncov-diagnostics-development.html.
As part of a multi-pronged response to the 2019-NcoV outbreak, BARDA has set up a website (see link below) to perform market research and keep the government informed about technologies that can be used to develop effective countermeasures against the coronavirus. Please note that this is only market research and there is no guarantee of any funding based on the information the company may provide—but it is important to hear from
your relevant stakeholders.
To support ongoing U.S. Government 2019-nCoV medical countermeasure development efforts, BARDA is pleased to open our EZ BAA program and seeks abstract submissions for select 2019-nCoV diagnostics only. Please see solicitation BAA-20-100-SOL-0002 AOI #4: 2019-nCoV for more information, and apply here.
Please see the following link on the DRIVe site: https://drive.hhs.gov/partner.html
Please Note: Special Instruction Added to EZ BAA-20-100-SOL-0002 - Coronoavirus - AOI #4.2
Another special instruction for COVID-19 was added to the EZ BAA, called AOI 4.2 (Non-clinical Models).
Here is the website to the EZ-BAA: https://beta.sam.gov/opp/560c7b048beb446b9ddf5e12744daf95/view
AOI #4 will be open for abstract submissions until 1700 HRS ET on 18 March 2020, unless otherwise extended. Additionally, award(s) expected to be made under these Special Instructions 002 will be less than $750,000 in total government funding.
Abstract submissions that do not conform to the requirements outlined in the EZ-BAA may be considered non‐responsive and will not be reviewed.
NOTE: Funding is limited, so we encourage any interested vendors to reach out to the appropriate Program Manager listed above before submitting an abstract as soon as possible.
The Assistant Secretary for Preparedness and Response (ASPR) is soliciting proposals for revolutionary advancements in health security products, technologies and innovations, specifically to invigorate operations, response, recovery and medical countermeasure development, deployment and distribution activities. ASPR is seeking innovative proposals to investigate approaches that enable revolutionary advances in science, technologies, or systems. Specifically excluded are basic science, research, development, prototype and process development, data science, clinical studies, and other activities that primarily result in evolutionary improvements to the existing state of the art. ASPR is seeking approaches that are outside the mainstream, challenge assumptions, and have the potential to radically change established practice, lead to extraordinary outcomes, and create entirely new fields and commercial market disruptions with wide-ranging impact that will protect Americans from 21st Century Health Threats.
ASPR Next Areas of Interest
AOI-1: Priority Medicines on Demand
Development of transformational devices for end-to-end pharmaceutical, vaccine and/or biologics production in small-scale, modular, continuous manufacturing platforms. ASPR is also interested in developing technologies that can transform drinking water to water for sterile injection, complete with physiological additives suitable for infusion, for production at point-of-delivery.
AOI-2: Dialysis Care in Disaster Settings
Development of next-generation, portable technologies for hemodialysis in disaster settings.
AOI-3: Medical Countermeasure Deployment and Dispensing
Development of capabilities to ensure rapid deployment and dispensing of medical countermeasures or other materials to emergency response locations. This is inclusive of, but not limited to, alternate delivery methods and dispensing solutions and the development of alternative delivery platforms for pharmaceutical, vaccine and biologic administration.
AOI-4: Real-Time Healthcare System Capacity Reporting
Develop capabilities that enable secure, confidential and controlled means to track healthcare provider capacity to respond to disasters in a dynamic and timely fashion.
AOI-5: Disaster Response and Recovery Intelligence
Develop capabilities that bring together deep learning, Artificial Intelligence and Machine Learning applications to forecast disaster impacts and automate replenishment of supplies during disasters.
AOI-6: Advanced Medical Interventions
Develop capabilities to address advanced health security vulnerabilities, establish trusted data platforms to secure health-related information and investigate linkages between clinical manifestation of disease and multi-omic indicators within dedicated US-based facilities to open new pipelines for medical countermeasure discovery
AOI-7: Telehealth Applications for Response and Recovery
Establish telehealth services for medical professionals and para-professionals to better assist state, local, tribal and territorial health systems during disaster response and recovery. These teams of medical professionals and para-professionals include advanced clinicians (nurse practitioners/physician assistants), medical officers, registered nurses, respiratory therapists, paramedics, pharmacists, safety specialists, logistical specialists, information technologists, communication and administrative specialists.
AOI-8: Health Security Innovation
This Area of Interest seeks revolutionary research ideas for topics not being addressed by ongoing ASPR programs or other published solicitations.
Office of the Assistant Secretary for Preparedness & Response (ASPR)
Department of Health and Human Services
330 Independence Ave. SW
Washington, District of Columbia 20201
United States Army Medical and Materiel Command (USAMRMC)
The United States Army Medical and Materiel Command's (USAMRMC) mission is to provide solutions to medical problems of importance to the American Service member at home and abroad, as well as to the general public at large. Extramural research and development programs play a vital role in the fulfillment of the objectives established by the USAMRMC.
The FY18-FY22 USAMRMC Broad Agency Announcement (BAA) is intended to solicit extramural research and development ideas. Research and development funded through the BAA are intended and expected to benefit and inform both military and civilian medical practice and knowledge.
Read more information.